3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Completed
1
Active not recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Other hematologic neoplasm
1
Conditions
Breast Neoplasms
629
Prostatic Neoplasms
371
Neoplasms
307
Carcinoma, Non-Small-Cell Lung
215
Lung Neoplasms
204
Colorectal Neoplasms
176
Multiple Myeloma
144
Pancreatic Neoplasms
136
Leukemia, Myeloid, Acute
128
Neoplasm Metastasis
124
Brain Neoplasms
117
Melanoma
116
Ovarian Neoplasms
103
Carcinoma, Hepatocellular
102
Precursor Cell Lymphoblastic Leukemia-Lymphoma
100
Glioblastoma
99
Uterine Cervical Neoplasms
97
Head and Neck Neoplasms
95
Squamous Cell Carcinoma of Head and Neck
94
Colonic Neoplasms
81
Stomach Neoplasms
80
Recurrence
80
Rectal Neoplasms
80
Urinary Bladder Neoplasms
77
Sarcoma
77
Triple Negative Breast Neoplasms
75
Carcinoma, Renal Cell
75
Lymphoma
71
Leukemia, Lymphocytic, Chronic, B-Cell
68
Lymphoma, Non-Hodgkin
67
Interventions
nilotinib
1
Dasatinib
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Active not recruiting
×
OTHER
×
Substance Withdrawal Syndrome
×
Clear all
NCT04147533
2024-11-26
HALF
Masaryk University
Phase 2
Active not recruiting
150 enrolled